ALDH1A1 and non-small cell lung carcinoma: Finally, to confirm the in vitro and in vivo findings, we analyzed the expression of ZEB1, BMI1, and ALDH1A1 by immunohistochemistry in lung cancer specimens obtained from 20 NSCLC patients before treatment and after relapse during treatment with gefitinib.